[Apomorphine as adjuvant treatment in idiopathic Parkinson syndrome].
28 patients suffering from idiopathic Parkinson's disease received subcutaneous apomorphine for the treatment of painful dystonia and of off-phases of long duration. After a mean period of 12.4 months 20 patients still used apomorphine. In this time the mean dose per injection had fallen from 2.5 mg to 2.1 mg and the mean number of daily applications from 2.6 to 2.2. Most patients considered dystonias and off-phases to respond satisfactorily to apomorphine. However, in most cases the treatment effect was impaired by side effects, especially nausea.
Bösch
M F
MF
Klinik für Neurologie, Kantonsspitals St. Gallen.
Ludin
H P
HP
D000368:Aged; D001058:Apomorphine / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D010302:Parkinson Disease, Secondary / Q000175:diagnosis / Q000188:drug therapy*
D007980:Levodopa; D001058:Apomorphine